For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- MTPC Terminates Joint Development of Roflumilast with Nycomed
February 7, 2011
- Present Industry's Opinions to Office of Medical Innovation: Mr Kawakami
February 7, 2011
- Sunovion Aims at Rapid Market Entry for Latuda by Replacing Existing Products
February 7, 2011
- Hayashibara Applies for Business Revitalization ADR
February 7, 2011
- FJPWA Calls For Resumption of Ryukaikon
February 7, 2011
- Takeda, MSD Call For Precautions on Similar Drug Names
February 7, 2011
- Meiji Seika, Fresenius Kabi Ally to Develop Anticancer Generics Business in Japan
February 7, 2011
- NBI's Mirapex Recommended for Approval
February 7, 2011
- Mochida Aims at Sales of ¥10 Bil. with Generics
February 7, 2011
- Making Whole of Japan Large Pharmaceutical Company: Prof. Nakamura
February 7, 2011
- Nichi-Iko to Raise ¥20 Bil. through Public Stock Offerings
February 7, 2011
- Pfizer Aims for Approval of 7 Products Each Year: President Umeda
February 7, 2011
- Gov't Rejects Court-Proposed Compromise in Iressa Lawsuits
February 7, 2011
- Torii Starts PIII Trial of Sublingual Desensitization Therapy for Cedar Pollinosis
February 7, 2011
- No. of Prescriptions Filled by GROWELL Up Sharply Due to Point Granting
January 31, 2011
- Takara Bio to Globally Develop HF10 Licensed from M's Science
January 31, 2011
- Xyzal Ranked No. 1 in GP Market: RepTrack Survey
January 31, 2011
- Takeda, Kyoto Univ. to Collaborate for CNS Drug Discovery
January 31, 2011
- aRigen Licenses Novel Anti-MRSA to GCC in South Korea
January 31, 2011
- Kyowa Kirin Licenses AMG827 from Amgen
January 31, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…